AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Organon & Co.

$13.64 +$6.40 (+88.47%)
NYSE · 14 Sep 2026 14:57 UTC
Previous Close
$13.64
Day Range
$13.64$13.67
Year Range
$5.69$13.79
Market Cap
3.58B
AVG Volume
3.11M
Trailing/Forward PE
17.27/3.76
PEG ratio
2.07
Dividend Yield
0.59%
Next Earnings Date
2026-11-09
Primary Exchange
New York Stock ExchangeUS
Revenue (USD) · TTM
02B4B6B8B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q26.13B
26 Q16.16B
25 Q46.22B
25 Q36.3B
25 Q26.28B
25 Q16.29B
24 Q46.4B
24 Q36.41B
24 Q26.35B
24 Q16.35B
Net Income (USD) · TTM
0500M1B1.5B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2209M
26 Q1246M
25 Q4187M
25 Q3501M
25 Q2700M
25 Q1750M
24 Q4864M
24 Q31.3B
24 Q21B
24 Q11.05B
Operating Income (USD) · TTM
0500M1B1.5B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q21.18B
26 Q11.19B
25 Q41.24B
25 Q31.3B
25 Q21.34B
25 Q11.4B
24 Q41.49B
24 Q31.5B
24 Q21.34B
24 Q11.35B
EBITDA (USD) · TTM
0500M1B1.5B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q21.31B
26 Q11.38B
25 Q41.3B
25 Q31.57B
25 Q21.52B
25 Q11.5B
24 Q41.61B
24 Q31.56B
24 Q21.43B
24 Q11.44B
Cash Flows (USD) · TTM
0250M500M750M1B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2498M
26 Q1614M
25 Q4404M
25 Q3566M
25 Q2482M
25 Q1601M
24 Q4603M
24 Q3661M
24 Q2802M
24 Q1458M
EPS (USD) · TTM
024624 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q20.77
26 Q10.93
25 Q40.71
25 Q31.92
25 Q22.69
25 Q12.88
24 Q43.33
24 Q35.04
24 Q23.89
24 Q14.09
Expenses (USD) · TTM
01B2B3BR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q22.3B
26 Q12.32B
25 Q42.38B
25 Q32.55B
25 Q22.54B
25 Q12.54B
24 Q42.56B
24 Q32.52B
24 Q22.64B
24 Q12.7B
Shares Outstanding (USD) · TTM
-150M-100M-50M050MBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
OGN Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-30.04M
26 Q1-59M
25 Q4-63M
25 Q3-78M
25 Q2-78M
25 Q1-82M
24 Q4-83M
24 Q3-86M
24 Q2-90M
24 Q1-64M
Dividends (USD)
00.10.20.3May 24Aug 24Nov 24Feb 25May 25Aug 25Nov 25Feb 26May 26Aug 26
OGN Dividends (USD) by quarter
PeriodDividends (USD)
Aug 260.02
May 260.02
Feb 260.02
Nov 250.02
Aug 250.02
May 250.02
Feb 250.28
Nov 240.28
Aug 240.28
May 240.28
Employee Count
02.5K5K7.5K10K20212022202320242025
OGN Employee Count by quarter
PeriodEmployee Count
202510K
202410K
202310K
202210K
20219.3K
PE Ratio
05101520med 3.81Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
OGN PE Ratio by quarter
PeriodPE Ratio
Sep 2617.14
Sep 2617.31
Aug 2617.29
Aug 2617.28
Aug 2617.24
Aug 2617.09
Jul 2617.03
Jul 2614.31
Jul 2614.31
Jul 2614.31
Jul 2614.34
Jun 2614.29
Jun 2614.21
Jun 2614.23
Jun 2614.14
May 2614.12
May 2614.21
May 2614.18
May 2614.13
May 2618.49
Apr 2615.67
Apr 2613.58
Apr 2612.29
Apr 268.85
Mar 268.13
Mar 268.39
Mar 268.83
Mar 269.13
Feb 2610.14
Feb 264.2
Feb 263.83
Feb 264.26
Jan 264.43
Jan 265.06
Jan 264.55
Jan 264.18
Jan 263.76
Dec 253.73
Dec 253.54
Dec 253.72
Dec 253.71
Nov 254
Nov 253.74
Nov 253.91
Nov 252.52
Oct 252.51
Oct 253.4
Oct 253.45
Oct 253.56
Oct 254.09
Sep 253.79
Sep 253.88
Sep 253.95
Sep 253.85
Aug 253.5
Aug 253.5
Aug 253.51
Aug 253.42
Aug 253.35
Jul 253.51
Jul 253.25
Jul 253.42
Jul 253.42
Jun 253.39
Jun 253.35
Jun 253.45
Jun 253.29
May 253.17
May 252.99
May 253.11
May 252.99
May 253.3
Apr 253.64
Apr 253.32
Apr 253.33
Apr 253.89
Mar 254.33
Mar 254.59
Mar 254.57
Mar 254.61
Feb 254.45
Feb 253.07
Feb 253.02
Feb 252.89
Jan 253.08
Jan 253.16
Jan 253.12
Jan 253.14
Jan 253.06
Dec 242.98
Dec 242.89
Dec 243.03
Dec 242.99
Nov 243.14
Nov 243.02
Nov 242.97
Nov 243.17
Nov 243.58
Oct 244.42
Oct 244.53
Free Cash Flow Yield
10%20%30%40%med 17.9%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
OGN Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 2613.9%
Sep 2613.76%
Aug 2613.78%
Aug 2613.79%
Aug 2613.82%
Aug 2613.94%
Jul 2614%
Jul 2617.44%
Jul 2617.44%
Jul 2617.44%
Jul 2617.4%
Jun 2617.47%
Jun 2617.56%
Jun 2617.55%
Jun 2617.65%
May 2617.68%
May 2617.56%
May 2617.6%
May 2617.66%
May 2611.68%
Apr 2613.79%
Apr 2615.91%
Apr 2617.59%
Apr 2624.42%
Mar 2626.59%
Mar 2625.75%
Mar 2624.45%
Mar 2623.67%
Feb 2621.3%
Feb 2626.88%
Feb 2629.46%
Feb 2626.52%
Jan 2625.49%
Jan 2622.31%
Jan 2624.85%
Jan 2627.05%
Jan 2630.07%
Dec 2530.32%
Dec 2531.88%
Dec 2530.36%
Dec 2530.49%
Nov 2528.24%
Nov 2530.24%
Nov 2528.91%
Nov 2527.35%
Oct 2527.47%
Oct 2520.24%
Oct 2519.98%
Oct 2519.32%
Oct 2516.84%
Sep 2518.16%
Sep 2517.74%
Sep 2517.41%
Sep 2517.86%
Aug 2519.68%
Aug 2519.66%
Aug 2519.64%
Aug 2520.11%
Aug 2523.9%
Jul 2522.83%
Jul 2524.64%
Jul 2523.45%
Jul 2523.4%
Jun 2523.64%
Jun 2523.9%
Jun 2523.21%
Jun 2524.38%
May 2525.28%
May 2526.82%
May 2525.78%
May 2526.76%
May 2524.3%
Apr 2519.18%
Apr 2521.04%
Apr 2520.93%
Apr 2517.93%
Mar 2516.13%
Mar 2515.2%
Mar 2515.28%
Mar 2515.16%
Feb 2515.69%
Feb 2516.57%
Feb 2516.8%
Feb 2517.56%
Jan 2516.5%
Jan 2516.07%
Jan 2516.31%
Jan 2516.2%
Jan 2516.63%
Dec 2417.05%
Dec 2417.61%
Dec 2416.78%
Dec 2416.98%
Nov 2416.18%
Nov 2416.8%
Nov 2417.08%
Nov 2416%
Nov 2414.21%
Oct 2418.17%
Oct 2417.7%
Price to Sales
0.20.40.60.8med 0.44Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
OGN Price to Sales by quarter
PeriodPrice to Sales
Sep 260.58
Sep 260.59
Aug 260.59
Aug 260.59
Aug 260.59
Aug 260.58
Jul 260.58
Jul 260.57
Jul 260.57
Jul 260.57
Jul 260.57
Jun 260.57
Jun 260.57
Jun 260.57
Jun 260.56
May 260.56
May 260.57
May 260.57
May 260.56
May 260.56
Apr 260.47
Apr 260.41
Apr 260.37
Apr 260.27
Mar 260.24
Mar 260.25
Mar 260.27
Mar 260.27
Feb 260.31
Feb 260.33
Feb 260.3
Feb 260.34
Jan 260.35
Jan 260.4
Jan 260.36
Jan 260.33
Jan 260.3
Dec 250.3
Dec 250.28
Dec 250.3
Dec 250.29
Nov 250.32
Nov 250.3
Nov 250.31
Nov 250.28
Oct 250.28
Oct 250.38
Oct 250.38
Oct 250.4
Oct 250.46
Sep 250.42
Sep 250.43
Sep 250.44
Sep 250.43
Aug 250.39
Aug 250.39
Aug 250.39
Aug 250.38
Aug 250.4
Jul 250.42
Jul 250.39
Jul 250.41
Jul 250.41
Jun 250.4
Jun 250.4
Jun 250.41
Jun 250.39
May 250.38
May 250.36
May 250.37
May 250.36
May 250.39
Apr 250.49
Apr 250.45
Apr 250.45
Apr 250.53
Mar 250.58
Mar 250.62
Mar 250.62
Mar 250.62
Feb 250.6
Feb 250.62
Feb 250.61
Feb 250.59
Jan 250.63
Jan 250.64
Jan 250.63
Jan 250.64
Jan 250.62
Dec 240.61
Dec 240.59
Dec 240.61
Dec 240.61
Nov 240.64
Nov 240.61
Nov 240.6
Nov 240.64
Nov 240.73
Oct 240.7
Oct 240.71
EV/EBITDA
6789med 7.53Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
OGN EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 268.42
Sep 268.45
Aug 268.45
Aug 268.45
Aug 268.44
Aug 268.42
Jul 268.41
Jul 267.93
Jul 267.93
Jul 267.93
Jul 267.93
Jun 267.92
Jun 267.91
Jun 267.91
Jun 267.9
May 267.89
May 267.91
May 267.91
May 267.9
May 268.99
Apr 268.59
Apr 268.29
Apr 268.1
Apr 267.61
Mar 267.5
Mar 267.54
Mar 267.6
Mar 267.65
Feb 267.79
Feb 266.52
Feb 266.4
Feb 266.53
Jan 266.59
Jan 266.79
Jan 266.62
Jan 266.51
Jan 266.37
Dec 256.36
Dec 256.31
Dec 256.36
Dec 256.36
Nov 256.45
Nov 256.37
Nov 256.42
Nov 256.63
Oct 256.63
Oct 257.04
Oct 257.06
Oct 257.11
Oct 257.36
Sep 257.22
Sep 257.26
Sep 257.29
Sep 257.25
Aug 257.08
Aug 257.09
Aug 257.09
Aug 257.05
Aug 257.28
Jul 257.36
Jul 257.23
Jul 257.31
Jul 257.32
Jun 257.3
Jun 257.28
Jun 257.33
Jun 257.25
May 257.19
May 257.1
May 257.16
May 257.1
May 257.25
Apr 257.16
Apr 256.99
Apr 257
Apr 257.3
Mar 257.53
Mar 257.67
Mar 257.66
Mar 257.68
Feb 257.59
Feb 257.68
Feb 257.65
Feb 257.54
Jan 257.69
Jan 257.76
Jan 257.72
Jan 257.74
Jan 257.67
Dec 247.61
Dec 247.53
Dec 247.65
Dec 247.62
Nov 247.74
Nov 247.65
Nov 247.6
Nov 247.77
Nov 248.11
Oct 248.64
Oct 248.72
Price/Operating Cashflow
12345med 3.32Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
OGN Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 264.86
Sep 264.91
Aug 264.9
Aug 264.9
Aug 264.89
Aug 264.85
Jul 264.83
Jul 264.14
Jul 264.14
Jul 264.14
Jul 264.15
Jun 264.14
Jun 264.11
Jun 264.12
Jun 264.09
May 264.09
May 264.11
May 264.1
May 264.09
May 264.94
Apr 264.19
Apr 263.63
Apr 263.28
Apr 262.36
Mar 262.17
Mar 262.24
Mar 262.36
Mar 262.44
Feb 262.71
Feb 262.22
Feb 262.02
Feb 262.25
Jan 262.34
Jan 262.67
Jan 262.4
Jan 262.21
Jan 261.98
Dec 251.97
Dec 251.87
Dec 251.96
Dec 251.96
Nov 252.11
Nov 251.97
Nov 252.06
Nov 252.13
Oct 252.12
Oct 252.88
Oct 252.92
Oct 253.02
Oct 253.46
Sep 253.21
Sep 253.29
Sep 253.35
Sep 253.27
Aug 252.96
Aug 252.97
Aug 252.97
Aug 252.9
Aug 252.68
Jul 252.81
Jul 252.6
Jul 252.73
Jul 252.74
Jun 252.71
Jun 252.68
Jun 252.76
Jun 252.63
May 252.53
May 252.39
May 252.49
May 252.39
May 252.64
Apr 253.35
Apr 253.05
Apr 253.07
Apr 253.58
Mar 253.98
Mar 254.22
Mar 254.2
Mar 254.24
Feb 254.09
Feb 254.22
Feb 254.16
Feb 253.98
Jan 254.24
Jan 254.35
Jan 254.28
Jan 254.31
Jan 254.2
Dec 244.1
Dec 243.97
Dec 244.16
Dec 244.12
Nov 244.32
Nov 244.16
Nov 244.09
Nov 244.37
Nov 244.92
Oct 244.14
Oct 244.25
Price to Book
010203040med 3.88Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
OGN Price to Book by quarter
PeriodPrice to Book
Sep 263.56
Sep 263.6
Aug 263.59
Aug 263.59
Aug 263.58
Aug 263.55
Jul 263.54
Jul 263.9
Jul 263.9
Jul 263.9
Jul 263.91
Jun 263.89
Jun 263.87
Jun 263.88
Jun 263.85
May 263.85
May 263.87
May 263.86
May 263.85
May 264.6
Apr 263.9
Apr 263.38
Apr 263.05
Apr 262.2
Mar 262.02
Mar 262.09
Mar 262.2
Mar 262.27
Feb 262.52
Feb 262.32
Feb 262.12
Feb 262.36
Jan 262.45
Jan 262.8
Jan 262.51
Jan 262.31
Jan 262.08
Dec 252.06
Dec 251.96
Dec 252.06
Dec 252.05
Nov 252.21
Nov 252.07
Nov 252.16
Nov 252.4
Oct 252.39
Oct 253.25
Oct 253.29
Oct 253.4
Oct 253.9
Sep 253.62
Sep 253.71
Sep 253.78
Sep 253.68
Aug 253.34
Aug 253.34
Aug 253.35
Aug 253.27
Aug 254.64
Jul 254.86
Jul 254.5
Jul 254.73
Jul 254.74
Jun 254.69
Jun 254.64
Jun 254.78
Jun 254.55
May 254.39
May 254.13
May 254.3
May 254.14
May 254.56
Apr 256.66
Apr 256.07
Apr 256.1
Apr 257.12
Mar 257.92
Mar 258.4
Mar 258.36
Mar 258.43
Feb 258.14
Feb 258.09
Feb 257.98
Feb 257.64
Jan 258.13
Jan 258.34
Jan 258.22
Jan 258.28
Jan 258.06
Dec 247.87
Dec 247.62
Dec 247.99
Dec 247.9
Nov 248.29
Nov 247.98
Nov 247.85
Nov 248.38
Nov 249.44
Oct 2430.66
Oct 2431.46
Organon & Co.
OGN
Stockpicker

Video analysis: OGN

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: OGN

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

businesswire.com · 14 Sep 2026

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.

Orogen Royalties Acquires the Serpent Gold Project in Nevada

accessnewswire.com · 10 Sep 2026

Orogen Royalties Acquires the Serpent Gold Project in Nevada

VANCOUVER, BC / ACCESS Newswire / September 10, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce the acquisition of the Serpent gold project in Nevada, USA. Project Highlights Serpent is a district scale, low-sulphidation epithermal gold target located in central Nevada Focused on a series of gold-bearing structures within an eight-kilometre trend of alteration Highly anomalous gold in rocks (up to 0.95 grams per tonne ("g/t") gold) associated with the shallow expression of an epithermal deposit Underexplored with no evidence of historical drilling Generated in partnership with Altius Minerals Corporation The Serpent project is available for option or sale.

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

zacks.com · 8 Sep 2026

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Orogen Royalties Acquires Two Gold Projects in Southwest Utah

accessnewswire.com · 2 Sep 2026

Orogen Royalties Acquires Two Gold Projects in Southwest Utah

VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA. Project Highlights Two low-sulphidation epithermal targets located in caldera complexes of southwest Utah Toro de Oro is centered on an extensive footprint of steam cap alteration and chalcedonic vein sets indicating the high-level expression of an epithermal system, geologically similar to AngloGold Ashanti's Arthur Project El Gigante contains two separate quartz veins up to and exceeding three metres wide and over 350 metres long with strong similarities to the surface expression of First Majestic's Ermitaño vein.

Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN

defenseworld.net · 29 Aug 2026

Bank of America Corp DE Has $4.42 Million Stock Position in Organon & Co. $OGN

Bank of America Corp DE reduced its position in shares of Organon and Co. (NYSE: OGN) by 58.5% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 738,502 shares of the company's stock after selling 1,041,346 shares during the period. Bank of America

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

globenewswire.com · 27 Aug 2026

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women's experiences of menopause and the menopausal transition, Can-RISE is led by PWHR with funding support from WHCC.

Organon & Co. (NYSE:OGN) Sets New 52-Week High  – Still a Buy?

defenseworld.net · 25 Aug 2026

Organon & Co. (NYSE:OGN) Sets New 52-Week High – Still a Buy?

Organon and Co. (NYSE: OGN - Get Free Report) reached a new 52-week high during trading on Tuesday. The stock traded as high as $13.76 and last traded at $13.7540, with a volume of 4583387 shares trading hands. The stock had previously closed at $13.75. Analyst Ratings Changes Several research firms have recently weighed in

Orogen Royalties Acquires a Royalty on the Haldane Silver Project

accessnewswire.com · 20 Aug 2026

Orogen Royalties Acquires a Royalty on the Haldane Silver Project

VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / (TSXV:OGN)(OTCQX:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce it has acquired a 2% Net Smelter Return ("NSR") royalty (the "Royalty") on the Haldane silver project in Yukon Territory, Canada. Haldane Royalty Highlights 1,2,3,4 Haldane is a high-grade silver project owned by Silver North Resources Ltd.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.